171 related articles for article (PubMed ID: 32103982)
21. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
22. Highly Expressed CYBRD1 Associated with Glioma Recurrence Regulates the Immune Response of Glioma Cells to Interferon.
Qing M; Zhou J; Chen W; Cheng L
Evid Based Complement Alternat Med; 2021; 2021():2793222. PubMed ID: 34326882
[TBL] [Abstract][Full Text] [Related]
23. Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.
Cao JY; Guo Q; Guan GF; Zhu C; Zou CY; Zhang LY; Cheng W; Wang GL; Cheng P; Wu AH; Li GY
Aging (Albany NY); 2020 Jan; 12(2):1656-1684. PubMed ID: 32003759
[TBL] [Abstract][Full Text] [Related]
24. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
25. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
26. Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
Happold C; Roth P; Silginer M; Florea AM; Lamszus K; Frei K; Deenen R; Reifenberger G; Weller M
Mol Cancer Ther; 2014 Apr; 13(4):948-61. PubMed ID: 24526161
[TBL] [Abstract][Full Text] [Related]
27. Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme.
Sun R; Pan Y; Mu L; Ma Y; Shen H; Long Y
Front Genet; 2021; 12():768930. PubMed ID: 34733320
[No Abstract] [Full Text] [Related]
28. Development of an Immune-Related Prognostic Index Associated With Glioblastoma.
Jiang Z; Shi Y; Zhao W; Zhang Y; Xie Y; Zhang B; Tan G; Wang Z
Front Neurol; 2021; 12():610797. PubMed ID: 34093386
[No Abstract] [Full Text] [Related]
29. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
30. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.
Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408
[TBL] [Abstract][Full Text] [Related]
31. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
Front Immunol; 2020; 11():585034. PubMed ID: 33193404
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.
Ning W; Qiu Z; Ji X; Wang X; An Y; Wang S; Zhang H
J Mol Neurosci; 2020 Oct; 70(10):1501-1511. PubMed ID: 32495005
[TBL] [Abstract][Full Text] [Related]
33. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
34. Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.
Zhang H; Fan F; Yu Y; Wang Z; Liu F; Dai Z; Zhang L; Liu Z; Cheng Q
J Transl Med; 2020 Aug; 18(1):305. PubMed ID: 32762688
[TBL] [Abstract][Full Text] [Related]
35. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
36. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
37. Specific clinical and immune features of CD68 in glioma via 1,024 samples.
Wang L; Zhang C; Zhang Z; Han B; Shen Z; Li L; Liu S; Zhao X; Ye F; Zhang Y
Cancer Manag Res; 2018; 10():6409-6419. PubMed ID: 30568502
[TBL] [Abstract][Full Text] [Related]
38. CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas.
Xu S; Li X; Tang L; Liu Z; Yang K; Cheng Q
Front Mol Biosci; 2021; 8():706949. PubMed ID: 34540893
[No Abstract] [Full Text] [Related]
39. Characterization of ferroptosis signature to evaluate the predict prognosis and immunotherapy in glioblastoma.
Zhu X; Zhou Y; Ou Y; Cheng Z; Han D; Chu Z; Pan S
Aging (Albany NY); 2021 Jul; 13(13):17655-17672. PubMed ID: 34244461
[TBL] [Abstract][Full Text] [Related]
40. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
